Antoni Liebert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antoni Liebert has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adam Niedziela
Warsaw Medical University, 02-091 Warsaw, Poland
7 shared publications - Dominika Domanowska
Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
7 shared publications - Hanna Wilska
Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
7 shared publications - Martyna Kaplińska
Warsaw Medical University, 02-091 Warsaw, Poland
7 shared publications - Natalia Klimek
Warsaw Medical University, 02-091 Warsaw, Poland
7 shared publications - Karol Krupiniewicz
Janusz Korczak Provincial Specialist Hospital in Słupsk, 76-200 Słupsk, Poland
5 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
NORADRENALINE OR DOPAMINE IN CARDIOGENIC SHOCK - A LITERATURE REVIEW
Introduction and purpose: Cardiogenic shock is a clinically specific cause of death that is hard to treat, and choosing the most effective medication remains a major clinical challenge. The aim of this study is to provide key information about this clinical condition and to compare the drugs most frequently used in the treatment of cardiogenic shock: noradrenaline and dopamine. Materials and methods: A literature search was conducted using the medical database PubMed and Google Scholar. Articles were retrieved using the keywords: ,,Noradrenaline”, ,,Dopamine”, ,,Cardiogenic shock”, ,,Hypotension” in appropriate configuration. Results: Four studies were found with relevant topics. One of these studies was excluded due to different vasopressors being compared in one of the trials considered in the meta-analysis. Finally, 3 scientific articles were systematically analyzed in our work. Conclusions: According to the available medical literature, recommendations, and guidelines, the use of noradrenaline in patients with cardiogenic shock is usually the most appropriate choice. However, the choice of dopamine is also available but it has been linked with a higher risk of complications linked with cardiac arrhythmias.
- 24 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessNORADRENALINE OR DOPAMINE IN CARDIOGENIC SHOCK - A LITERATURE REVIEW
Introduction and purpose: Cardiogenic shock is a clinically specific cause of death that is hard to treat, and choosing the most effective medication remains a major clinical challenge. The aim of this study is to provide key information about this clinical condition and to compare the drugs most frequently used in the treatment of cardiogenic shock: noradrenaline and dopamine. Materials and methods: A literature search was conducted using the medical database PubMed and Google Scholar. Articles were retrieved using the keywords: ,,Noradrenaline”, ,,Dopamine”, ,,Cardiogenic shock”, ,,Hypotension” in appropriate configuration. Results: Four studies were found with relevant topics. One of these studies was excluded due to different vasopressors being compared in one of the trials considered in the meta-analysis. Finally, 3 scientific articles were systematically analyzed in our work. Conclusions: According to the available medical literature, recommendations, and guidelines, the use of noradrenaline in patients with cardiogenic shock is usually the most appropriate choice. However, the choice of dopamine is also available but it has been linked with a higher risk of complications linked with cardiac arrhythmias.
- Open Access
- 30 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
The Impact of Malnutrition on the Wound Healing Process: A Summary of Current Knowledge
Aim: The aim of this narrative review was to summarize current PubMed-indexed evidence on the impact of malnutrition on the wound healing process and to synthesize clinical data regarding nutritional interventions that may improve wound outcomes. Materials and Methods: A narrative literature review was conducted based exclusively on peer-reviewed studies indexed in PubMed. Experimental studies, observational studies, randomized controlled trials, and systematic reviews addressing nutrition, malnutrition, and wound healing were included. Evidence from the provided publications and their referenced bibliographies was analyzed and synthesized qualitatively. Results: Clinical and experimental evidence shows that malnutrition causes disruptions of all phases of wound healing by disturbing inflammatory control, decreasing collagen deposition, delaying angiogenesis and reducing fibroblast activity. Observational studies report a high prevalence of malnutrition among patients with chronic wounds, particularly pressure injuries and venous leg ulcers, and associate poor nutritional status with slower wound closure and higher complication rates. Randomized clinical trials and systematic reviews indicate that targeted oral nutritional supplementation, especially high-protein formulas enriched with zinc, arginine and antioxidants, improve healing effects in patients with pressure ulcers when they are used as an adjunct to standard wound care.
- 30 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessThe Impact of Malnutrition on the Wound Healing Process: A Summary of Current Knowledge
Aim: The aim of this narrative review was to summarize current PubMed-indexed evidence on the impact of malnutrition on the wound healing process and to synthesize clinical data regarding nutritional interventions that may improve wound outcomes. Materials and Methods: A narrative literature review was conducted based exclusively on peer-reviewed studies indexed in PubMed. Experimental studies, observational studies, randomized controlled trials, and systematic reviews addressing nutrition, malnutrition, and wound healing were included. Evidence from the provided publications and their referenced bibliographies was analyzed and synthesized qualitatively. Results: Clinical and experimental evidence shows that malnutrition causes disruptions of all phases of wound healing by disturbing inflammatory control, decreasing collagen deposition, delaying angiogenesis and reducing fibroblast activity. Observational studies report a high prevalence of malnutrition among patients with chronic wounds, particularly pressure injuries and venous leg ulcers, and associate poor nutritional status with slower wound closure and higher complication rates. Randomized clinical trials and systematic reviews indicate that targeted oral nutritional supplementation, especially high-protein formulas enriched with zinc, arginine and antioxidants, improve healing effects in patients with pressure ulcers when they are used as an adjunct to standard wound care.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
EFFECTS OF COLD-WATER IMMERSION (≤14°C) ON PHYSIOLOGICAL RECOVERY, INFLAMMATION, AND PERFORMANCE: A SYSTEMATIC REVIEW OF HUMAN STUDIES
Background: Cold-water immersion (CWI) is a widely used recovery strategy among athletes and physically active individuals, commonly applied to reduce post-exercise fatigue and muscle soreness. Although CWI is known to induce rapid thermoregulatory and autonomic responses, the magnitude and direction of its effects appear strongly dependent on protocol parameters such as water temperature, exposure duration, and immersion depth. Evidence remains fragmented, and many previous reviews have combined cold modalities above 14°C or non-immersion cryotherapies, limiting clarity regarding true cold-water exposure. Aim: This review synthesizes current evidence regarding the physiological and performance-related effects of CWI performed at ≤14°C for ≥1 minute in healthy adults, with particular focus on recovery, inflammatory and immune responses, cardiovascular function, and neuromuscular performance. Methods: We systematically searched PubMed, Google Scholar, and Cochrane Library using terms including cold water immersion, CWI, ice bath, cold-water immersion recovery, cold immersion muscle soreness, cold immersion performance, and related combinations. Only open-access human experimental studies reporting direct immersion ≤14°C were included. Twenty studies met the eligibility criteria. Results: CWI consistently reduced delayed-onset muscle soreness and improved subjective recovery across protocols. Performance outcomes were variable: benefits were more evident in high-intensity and intermittent sports, whereas strength and endurance recovery showed mixed results. Inflammatory, immune, and oxidative markers demonstrated context-dependent modulation. Cardiovascular and metabolic responses increased with lower temperatures and longer exposures, and limited evidence suggests potential adaptive effects following repeated immersion. Conclusion: CWI at ≤14°C is an effective modality for reducing muscle soreness and enhancing perceived recovery post-exercise, with conditional benefits for performance depending on protocol and sport type. Physiological responses are heterogeneous, underscoring the need for standardized protocols and further longitudinal research to clarify dose–response relationships and long-term adaptive outcomes.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessEFFECTS OF COLD-WATER IMMERSION (≤14°C) ON PHYSIOLOGICAL RECOVERY, INFLAMMATION, AND PERFORMANCE: A SYSTEMATIC REVIEW OF HUMAN STUDIES
Background: Cold-water immersion (CWI) is a widely used recovery strategy among athletes and physically active individuals, commonly applied to reduce post-exercise fatigue and muscle soreness. Although CWI is known to induce rapid thermoregulatory and autonomic responses, the magnitude and direction of its effects appear strongly dependent on protocol parameters such as water temperature, exposure duration, and immersion depth. Evidence remains fragmented, and many previous reviews have combined cold modalities above 14°C or non-immersion cryotherapies, limiting clarity regarding true cold-water exposure. Aim: This review synthesizes current evidence regarding the physiological and performance-related effects of CWI performed at ≤14°C for ≥1 minute in healthy adults, with particular focus on recovery, inflammatory and immune responses, cardiovascular function, and neuromuscular performance. Methods: We systematically searched PubMed, Google Scholar, and Cochrane Library using terms including cold water immersion, CWI, ice bath, cold-water immersion recovery, cold immersion muscle soreness, cold immersion performance, and related combinations. Only open-access human experimental studies reporting direct immersion ≤14°C were included. Twenty studies met the eligibility criteria. Results: CWI consistently reduced delayed-onset muscle soreness and improved subjective recovery across protocols. Performance outcomes were variable: benefits were more evident in high-intensity and intermittent sports, whereas strength and endurance recovery showed mixed results. Inflammatory, immune, and oxidative markers demonstrated context-dependent modulation. Cardiovascular and metabolic responses increased with lower temperatures and longer exposures, and limited evidence suggests potential adaptive effects following repeated immersion. Conclusion: CWI at ≤14°C is an effective modality for reducing muscle soreness and enhancing perceived recovery post-exercise, with conditional benefits for performance depending on protocol and sport type. Physiological responses are heterogeneous, underscoring the need for standardized protocols and further longitudinal research to clarify dose–response relationships and long-term adaptive outcomes.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
THE MICROBIOTA–GUT–BRAIN AXIS IN MENTAL HEALTH: MECHANISMS, CLINICAL EVIDENCE, AND EMERGING THERAPEUTIC STRATEGIES
Interactions between intestinal microbiota and the central nervous system have become one of the most dynamic areas of biomedical research. Accumulating evidence demonstrates that gut microorganisms influence emotional regulation, cognition, and stress responsiveness through complex neural, immune, and metabolic pathways. This review provides an extensive overview of current knowledge regarding the microbiota–gut–brain axis, with particular emphasis on depression and anxiety disorders. Mechanistic insights, human clinical trials, and therapeutic perspectives including probiotics, prebiotics, dietary modulation, and fecal microbiota transplantation are discussed. Despite promising findings, important methodological limitations remain, and further research is required to translate microbiota-based interventions into routine psychiatric practice.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessTHE MICROBIOTA–GUT–BRAIN AXIS IN MENTAL HEALTH: MECHANISMS, CLINICAL EVIDENCE, AND EMERGING THERAPEUTIC STRATEGIES
Interactions between intestinal microbiota and the central nervous system have become one of the most dynamic areas of biomedical research. Accumulating evidence demonstrates that gut microorganisms influence emotional regulation, cognition, and stress responsiveness through complex neural, immune, and metabolic pathways. This review provides an extensive overview of current knowledge regarding the microbiota–gut–brain axis, with particular emphasis on depression and anxiety disorders. Mechanistic insights, human clinical trials, and therapeutic perspectives including probiotics, prebiotics, dietary modulation, and fecal microbiota transplantation are discussed. Despite promising findings, important methodological limitations remain, and further research is required to translate microbiota-based interventions into routine psychiatric practice.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
WORK PRODUCTIVITY AND COGNITIVE LOAD ACROSS MENSTRUAL CYCLE PHASES: A NARRATIVE LITERATURE REVIEW
Hormonal fluctuations across the menstrual cycle are increasingly recognized as meaningful contributors to variations in cognition, emotional regulation, and daily functioning. However, empirical evidence remains fragmented across disciplines, with studies differing widely in methodological rigor, outcome measures, and approaches to menstrual phase classification. This lack of integration limits the field’s ability to draw coherent conclusions about how cycle-related changes influence cognitive load and work productivity—domains of growing significance for women’s health and occupational wellbeing. This narrative review addresses this gap by synthesizing findings from nineteen empirical studies spanning neuroscience, psychology, occupational health, and digital menstrual tracking. A structured search of PubMed, Scopus, and Web of Science was used to identify eligible studies. Data were then extracted using a standardized analytical protocol. The findings reveal domain-specific patterns of cognitive variation, with the most consistent differences observed in reaction time, attentional stability, and temporal anticipation. Cognitive-emotional processes—including rumination, stress reactivity, and negative attentional bias—showed particularly pronounced fluctuations during the luteal and premenstrual phases, especially among individuals with PMS or PMDD, and were associated with reduced efficiency, motivation, and routine management. Digital tracking tools provided additional insight into menstrual variability but demonstrated methodological limitations that affect their reliability for studying cognitive and functional outcomes. Overall, the evidence indicates that menstrual-cycle-related changes in cognition and emotional processing interact with symptom burden to shape cognitive load and everyday productivity. Strengthening methodological rigor, incorporating validated measures, and improving menstrual health literacy may enhance both research precision and practical strategies for supporting individuals across menstrual cycle phases.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessWORK PRODUCTIVITY AND COGNITIVE LOAD ACROSS MENSTRUAL CYCLE PHASES: A NARRATIVE LITERATURE REVIEW
Hormonal fluctuations across the menstrual cycle are increasingly recognized as meaningful contributors to variations in cognition, emotional regulation, and daily functioning. However, empirical evidence remains fragmented across disciplines, with studies differing widely in methodological rigor, outcome measures, and approaches to menstrual phase classification. This lack of integration limits the field’s ability to draw coherent conclusions about how cycle-related changes influence cognitive load and work productivity—domains of growing significance for women’s health and occupational wellbeing. This narrative review addresses this gap by synthesizing findings from nineteen empirical studies spanning neuroscience, psychology, occupational health, and digital menstrual tracking. A structured search of PubMed, Scopus, and Web of Science was used to identify eligible studies. Data were then extracted using a standardized analytical protocol. The findings reveal domain-specific patterns of cognitive variation, with the most consistent differences observed in reaction time, attentional stability, and temporal anticipation. Cognitive-emotional processes—including rumination, stress reactivity, and negative attentional bias—showed particularly pronounced fluctuations during the luteal and premenstrual phases, especially among individuals with PMS or PMDD, and were associated with reduced efficiency, motivation, and routine management. Digital tracking tools provided additional insight into menstrual variability but demonstrated methodological limitations that affect their reliability for studying cognitive and functional outcomes. Overall, the evidence indicates that menstrual-cycle-related changes in cognition and emotional processing interact with symptom burden to shape cognitive load and everyday productivity. Strengthening methodological rigor, incorporating validated measures, and improving menstrual health literacy may enhance both research precision and practical strategies for supporting individuals across menstrual cycle phases.
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 6 (3(47))
NEW PERSPECTIVES ON ALZHEIMER’S DISEASE TREATMENT: A STRUCTURED SCIENTIFIC REVIEW (2020–2025)
Background: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with current therapies offering only modest symptomatic benefits. In recent years, multiple mechanistic approaches have advanced into clinical testing, reshaping therapeutic strategies. Objective: This review synthesizes evidence from the past five years on emerging treatments for AD, highlighting novel disease-modifying agents, biomarker innovations, and adjunctive strategies. Methods: A structured literature search was conducted across PubMed, Embase, and ClinicalTrials.gov for studies published between January 2020 and July 2025. Peer-reviewed articles, pivotal clinical trials, and regulatory documents were included. Findings were organized into five thematic domains: anti-amyloid therapies, tau-targeted interventions, neuroinflammation and innate immunity, metabolic and repurposed drugs, and emerging technologies for drug delivery and diagnostics. Results: Anti-amyloid monoclonal antibodies, including lecanemab and donanemab, demonstrated clinically meaningful slowing of cognitive decline in early AD, leading to regulatory approvals. However, safety concerns, particularly amyloid-related imaging abnormalities, remain critical considerations. Tau-targeting therapies have shown modest biomarker and clinical effects, while immune-modulating agents, such as TREM2 agonists, represent promising novel approaches. GLP-1 receptor agonists, intranasal insulin, and lifestyle-based multidomain interventions target metabolic and systemic contributors to AD, with mixed but encouraging results. Technological advances, including focused ultrasound for blood–brain barrier opening and blood-based biomarkers (e.g., plasma p-tau217, GFAP, NfL), are transforming diagnosis and trial design. Despite progress, challenges remain regarding safety, generalizability, and equitable access. Conclusion: AD therapeutics are entering a transformative phase, shifting from purely symptomatic management toward disease modification. Anti-amyloid therapies provide proof of principle but require optimization of safety and implementation. Parallel efforts targeting tau, neuroinflammation, and systemic pathways, coupled with advances in biomarker-driven precision medicine, suggest that future management will likely rely on combination strategies tailored to individual biological profiles.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 6 (3(47))
Open AccessNEW PERSPECTIVES ON ALZHEIMER’S DISEASE TREATMENT: A STRUCTURED SCIENTIFIC REVIEW (2020–2025)
Background: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with current therapies offering only modest symptomatic benefits. In recent years, multiple mechanistic approaches have advanced into clinical testing, reshaping therapeutic strategies. Objective: This review synthesizes evidence from the past five years on emerging treatments for AD, highlighting novel disease-modifying agents, biomarker innovations, and adjunctive strategies. Methods: A structured literature search was conducted across PubMed, Embase, and ClinicalTrials.gov for studies published between January 2020 and July 2025. Peer-reviewed articles, pivotal clinical trials, and regulatory documents were included. Findings were organized into five thematic domains: anti-amyloid therapies, tau-targeted interventions, neuroinflammation and innate immunity, metabolic and repurposed drugs, and emerging technologies for drug delivery and diagnostics. Results: Anti-amyloid monoclonal antibodies, including lecanemab and donanemab, demonstrated clinically meaningful slowing of cognitive decline in early AD, leading to regulatory approvals. However, safety concerns, particularly amyloid-related imaging abnormalities, remain critical considerations. Tau-targeting therapies have shown modest biomarker and clinical effects, while immune-modulating agents, such as TREM2 agonists, represent promising novel approaches. GLP-1 receptor agonists, intranasal insulin, and lifestyle-based multidomain interventions target metabolic and systemic contributors to AD, with mixed but encouraging results. Technological advances, including focused ultrasound for blood–brain barrier opening and blood-based biomarkers (e.g., plasma p-tau217, GFAP, NfL), are transforming diagnosis and trial design. Despite progress, challenges remain regarding safety, generalizability, and equitable access. Conclusion: AD therapeutics are entering a transformative phase, shifting from purely symptomatic management toward disease modification. Anti-amyloid therapies provide proof of principle but require optimization of safety and implementation. Parallel efforts targeting tau, neuroinflammation, and systemic pathways, coupled with advances in biomarker-driven precision medicine, suggest that future management will likely rely on combination strategies tailored to individual biological profiles.
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
METFORMIN AND THE GUT MICROBIOTA: CHANGES AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW
Background: Metformin remains the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM), traditionally understood to act through hepatic glucose suppression and improved insulin sensitivity. However, mounting evidence indicates that metformin significantly influences the gut microbiota, which may underlie some of its metabolic and gastrointestinal effects Aim: This review explores metformin’s mechanisms of action via gut microbial modulation, its clinical effects, and side-effect implications, drawing upon recent primary and review literature. Methods: We performed comprehensive searches in databases including PubMed and Google Scholar,using terms such as metformin, mechanisms of metformin, gut microbiota, side effects of metformin, metformin mechanisms gut, and related combinations. We included studies published up to mid-2025, prioritizing human clinical trials, systematic reviews, and mechanistic animal studies. Results: Compelling evidence shows that metformin alters gut microbial composition—increasing taxa like Akkermansia muciniphila, Escherichia, and SCFA-producers—while reducing others. These shifts are linked to improved barrier integrity, altered bile acid signaling (e.g., FXR inhibition, GLP-1 increase), enhanced SCFA production, modulated metabolite profiles (e.g., BCAA, aromatic amino acids), and altered host glucose flux. Clinically, these microbiome changes likely contribute to metformin’s glucose-lowering, weight-modulating, and anti-inflammatory effects but may also underpin gastrointestinal side effects. Conclusion: The gut microbiota is a significant mediator of both beneficial and adverse effects of metformin. Ongoing and future research—especially RCTs and mechanistic human studies—will be critical for harnessing this interaction therapeutically.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
Open AccessMETFORMIN AND THE GUT MICROBIOTA: CHANGES AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW
Background: Metformin remains the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM), traditionally understood to act through hepatic glucose suppression and improved insulin sensitivity. However, mounting evidence indicates that metformin significantly influences the gut microbiota, which may underlie some of its metabolic and gastrointestinal effects Aim: This review explores metformin’s mechanisms of action via gut microbial modulation, its clinical effects, and side-effect implications, drawing upon recent primary and review literature. Methods: We performed comprehensive searches in databases including PubMed and Google Scholar,using terms such as metformin, mechanisms of metformin, gut microbiota, side effects of metformin, metformin mechanisms gut, and related combinations. We included studies published up to mid-2025, prioritizing human clinical trials, systematic reviews, and mechanistic animal studies. Results: Compelling evidence shows that metformin alters gut microbial composition—increasing taxa like Akkermansia muciniphila, Escherichia, and SCFA-producers—while reducing others. These shifts are linked to improved barrier integrity, altered bile acid signaling (e.g., FXR inhibition, GLP-1 increase), enhanced SCFA production, modulated metabolite profiles (e.g., BCAA, aromatic amino acids), and altered host glucose flux. Clinically, these microbiome changes likely contribute to metformin’s glucose-lowering, weight-modulating, and anti-inflammatory effects but may also underpin gastrointestinal side effects. Conclusion: The gut microbiota is a significant mediator of both beneficial and adverse effects of metformin. Ongoing and future research—especially RCTs and mechanistic human studies—will be critical for harnessing this interaction therapeutically.
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
MIRIKIZUMAB – THE EFFICACY OF TREATMENT IN INFLAMMATORY BOWEL DISEASE
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of interleukin IL-23. In recent years, it has been the subject of numerous clinical trials as a potential new therapy for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Additionally, mirikizumab has been evaluated in clinical trials as a possible treatment for plaque psoriasis. Clinical trial results in ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for the treatment of adult patients with moderately to severely active disease. Despite promising clinical trial outcomes, mirikizumab has not yet been approved for the treatment of Crohn’s disease. This review focuses on summarizing findings from clinical trials investigating mirikizumab in inflammatory bowel diseases. The information is derived from scientific publications indexed in PubMed, searched using the terms “mirikizumab” and “IL-23” and published up to February 2025, as well as from published clinical trial results on mirikizumab.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
Open AccessMIRIKIZUMAB – THE EFFICACY OF TREATMENT IN INFLAMMATORY BOWEL DISEASE
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of interleukin IL-23. In recent years, it has been the subject of numerous clinical trials as a potential new therapy for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Additionally, mirikizumab has been evaluated in clinical trials as a possible treatment for plaque psoriasis. Clinical trial results in ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for the treatment of adult patients with moderately to severely active disease. Despite promising clinical trial outcomes, mirikizumab has not yet been approved for the treatment of Crohn’s disease. This review focuses on summarizing findings from clinical trials investigating mirikizumab in inflammatory bowel diseases. The information is derived from scientific publications indexed in PubMed, searched using the terms “mirikizumab” and “IL-23” and published up to February 2025, as well as from published clinical trial results on mirikizumab.
- Open Access
- 5 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
LUSPATERCEPT – AN INNOVATIVE APPROACH TO THE TREATMENT OF ANEMIA IN BETA-THALASSEMIA AND MYELODYSPLASTIC SYNDROMES
Ineffective erythropoiesis (IE) is a hallmark of several hematologic disorders, including β-thalassemia and myelodysplastic syndromes (MDS), leading to chronic anemia and transfusion dependence. IE is often driven by disrupted late-stage erythroid maturation, mediated by overactivation of the Smad2/3 signaling pathway within the transforming growth factor-β (TGF-β) superfamily. This review summarizes current evidence on the mechanism of action and clinical efficacy of luspatercept, a novel activin receptor ligand trap that enhances erythroid maturation by inhibiting Smad2/3 signaling. A literature search was conducted using PubMed through February 2025, focusing on clinical trials and mechanistic studies of luspatercept in β-thalassemia and MDS. In β-thalassemia, luspatercept significantly reduced transfusion burden in phase I–III trials. The pivotal BELIEVE study demonstrated that ≥33% transfusion reduction was achieved in a significantly higher proportion of patients receiving luspatercept compared to placebo. In low-risk MDS (LR-MDS), phase II PACE-MDS and phase III COMMANDS trials showed that luspatercept induced erythroid response (HI-E) and transfusion independence (RBC-TI) in a substantial proportion of patients. COMMANDS further revealed that luspatercept outperformed epoetin alfa in achieving ≥12-week RBC-TI and ≥1.5 g/dL hemoglobin increase, regardless of SF3B1 mutation status or baseline erythropoietin levels. Luspatercept presents a promising treatment strategy for IE in β-thalassemia and LR-MDS. Its ability to promote erythropoiesis, reduce transfusion needs, and maintain a favorable safety profile supports its potential as a new standard of care. Ongoing research will help define its role across broader patient populations.
- 5 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessLUSPATERCEPT – AN INNOVATIVE APPROACH TO THE TREATMENT OF ANEMIA IN BETA-THALASSEMIA AND MYELODYSPLASTIC SYNDROMES
Ineffective erythropoiesis (IE) is a hallmark of several hematologic disorders, including β-thalassemia and myelodysplastic syndromes (MDS), leading to chronic anemia and transfusion dependence. IE is often driven by disrupted late-stage erythroid maturation, mediated by overactivation of the Smad2/3 signaling pathway within the transforming growth factor-β (TGF-β) superfamily. This review summarizes current evidence on the mechanism of action and clinical efficacy of luspatercept, a novel activin receptor ligand trap that enhances erythroid maturation by inhibiting Smad2/3 signaling. A literature search was conducted using PubMed through February 2025, focusing on clinical trials and mechanistic studies of luspatercept in β-thalassemia and MDS. In β-thalassemia, luspatercept significantly reduced transfusion burden in phase I–III trials. The pivotal BELIEVE study demonstrated that ≥33% transfusion reduction was achieved in a significantly higher proportion of patients receiving luspatercept compared to placebo. In low-risk MDS (LR-MDS), phase II PACE-MDS and phase III COMMANDS trials showed that luspatercept induced erythroid response (HI-E) and transfusion independence (RBC-TI) in a substantial proportion of patients. COMMANDS further revealed that luspatercept outperformed epoetin alfa in achieving ≥12-week RBC-TI and ≥1.5 g/dL hemoglobin increase, regardless of SF3B1 mutation status or baseline erythropoietin levels. Luspatercept presents a promising treatment strategy for IE in β-thalassemia and LR-MDS. Its ability to promote erythropoiesis, reduce transfusion needs, and maintain a favorable safety profile supports its potential as a new standard of care. Ongoing research will help define its role across broader patient populations.
- Open Access
- 19 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
POSTOPERATIVE PAIN MANAGEMENT IN DENTISTRY: A NARRATIVE REVIEW OF THE USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Background. Postoperative pain is a frequent consequence of dental procedures and significantly affects patient comfort and recovery. The severity and duration of pain vary depending on the type of procedure and individual patient factors. Although it usually resolves within a few days, in some cases it may become chronic. Effective pain management is therefore essential. Aim. This review presents contemporary strategies for managing postoperative dental pain, with particular emphasis on the use and efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review was conducted using PubMed and Google Scholar. Relevant peer-reviewed original articles, systematic reviews, and clinical trials published in English were selected. The inclusion criteria focused on studies concerning the use of NSAIDs in various dental disciplines, including conservative dentistry, pediatric dentistry, orthodontics, periodontology, prosthetics, and oral and maxillofacial surgery. Articles not related to dental postoperative pain or NSAID use, case reports, and expert opinions were excluded. Results. NSAIDs such as ibuprofen, ketoprofen, and selective COX-2 inhibitors have proven effective in reducing postoperative dental pain across a broad range of procedures. Their mechanism involves cyclooxygenase inhibition and modulation of inflammatory pathways. In many clinical scenarios, NSAIDs surpass opioids and paracetamol alone in efficacy. Preoperative administration is often beneficial, especially in pediatric and orthodontic cases. Additional non-pharmacological methods, such as cryotherapy and laser therapy, further enhance outcomes. However, gastrointestinal, renal, and cardiovascular risks must be considered. Conclusions. NSAIDs are fundamental in managing postoperative dental pain due to their anti-inflammatory and analgesic properties. The best outcomes are achieved through a personalized, multimodal approach combining NSAIDs with non-pharmacological strategies, ensuring effective pain relief while minimizing adverse effects.
- 19 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessPOSTOPERATIVE PAIN MANAGEMENT IN DENTISTRY: A NARRATIVE REVIEW OF THE USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Background. Postoperative pain is a frequent consequence of dental procedures and significantly affects patient comfort and recovery. The severity and duration of pain vary depending on the type of procedure and individual patient factors. Although it usually resolves within a few days, in some cases it may become chronic. Effective pain management is therefore essential. Aim. This review presents contemporary strategies for managing postoperative dental pain, with particular emphasis on the use and efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review was conducted using PubMed and Google Scholar. Relevant peer-reviewed original articles, systematic reviews, and clinical trials published in English were selected. The inclusion criteria focused on studies concerning the use of NSAIDs in various dental disciplines, including conservative dentistry, pediatric dentistry, orthodontics, periodontology, prosthetics, and oral and maxillofacial surgery. Articles not related to dental postoperative pain or NSAID use, case reports, and expert opinions were excluded. Results. NSAIDs such as ibuprofen, ketoprofen, and selective COX-2 inhibitors have proven effective in reducing postoperative dental pain across a broad range of procedures. Their mechanism involves cyclooxygenase inhibition and modulation of inflammatory pathways. In many clinical scenarios, NSAIDs surpass opioids and paracetamol alone in efficacy. Preoperative administration is often beneficial, especially in pediatric and orthodontic cases. Additional non-pharmacological methods, such as cryotherapy and laser therapy, further enhance outcomes. However, gastrointestinal, renal, and cardiovascular risks must be considered. Conclusions. NSAIDs are fundamental in managing postoperative dental pain due to their anti-inflammatory and analgesic properties. The best outcomes are achieved through a personalized, multimodal approach combining NSAIDs with non-pharmacological strategies, ensuring effective pain relief while minimizing adverse effects.